Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 165

The DOI matches its Crossref record.

Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer

Zhang, Xiu Li, Yang, Yun Sheng, Xu, Dong Ping, Qu, Jian Hui, Guo, Ming Zhou, Gong, Yan, Huang, Jin · 2009 · World Journal of Surgery

Abstract

Background: Owing to the special importance of the HER family in tumorigenesis, the downstream signaling pathways and effectors have become the key molecules in the strategy of carcinoma‐targeted therapy. Recent evidence that HER3 is responsible for tumor resistance to therapeutic agents targeting EGFR or HER2/neu, along with the new findings that HER3 is involved in the process of dedifferentiation of gastric cancer (GC) have highlighted the critical role of HER3 in cancer research. HER3 is becoming a new targeted molecule in cancer treatment. Here, we comparatively investigated the expression of HER2/neu and HER3 in gastric cancer of two pathologic types (intestinal type and diffuse type) using immunohistochemistry (IHC) and analyzed the correlation between overexpression of HER2 and HER3 and clinicopathologic parameters. Methods: An IHC study for HER2 and HER3 was performed on 102 formalin‐fixed, paraffin‐embedded specimens of GC—60 intestinal and 42 diffuse types. The correlation between overexpression of HER2 and HER3 and clinicopathologic parameters was statistically analyzed. Results: In the GC group, overexpression of HER2 and HER3 was detected in 19 (18.6%) and 14 (13.7%) of 102 GC patients, respectively. In a nontumorous group of 102 specimens, 5 were HER2‐positive (4.9%) (18.6% vs. 4.9%, p < 0.01), and 2 were HER3‐positive (2.0%) (13.7% vs. 2.0%, p < 0.01). No co‐overexpression of HER2 and HER3 was observed. The intestinal type of GC exhibited a higher rate of HER2 overexpression than did the diffuse type (26.7% vs. 7.1%, p < 0.05), whereas the diffuse type of GC exhibited a significantly higher rate of HER3 overexpression than did the intestinal type (26.2% vs. 5.0%, p < 0.01). The overexpression rates of HER2 and HER3 in phase III–IV (TNM stage) disease were significantly higher than that in phase I–II disease (24.0% vs. 7.7%, p < 0.05 and 22.0% vs. 5.8%, p < 0.05, respectively). HER2 and HER3 overexpression was also correlated with a significantly worse survival (p = 0.046 and 0.024, respectively). Conclusions: The selective overexpression of HER2 and HER3 in the two histologic types of gastric cancer is strongly associated with a poor prognosis. Being an important member of the HER family, HER3 may become another candidate for molecular‐targeted therapy in gastric cancer, especially for the diffuse histologic type.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00268-009-0142-z

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 165

Metadata

Authors
Zhang, X. L., Yang, Y. S., Xu, D. P., Qu, J. H., Guo, M. Z., Gong, Y., & Huang, J.
Venue
World Journal of Surgery
Publisher
Wiley
Published
2009-07-28
Volume
33
Issue
10
Pages
2112-2118
ISSN
  • 0364-2313 (ISSN-L)
  • 1432-2323
OpenAlex
W2054390556
Cited by
165
References
0
FWCI
7.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer. https://app.cochat.ai/papers/10.1007/s00268-009-0142-z
The paper
Zhang, X. L., Yang, Y. S., Xu, D. P., Qu, J. H., Guo, M. Z., Gong, Y., & Huang, J. (2009). Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer. World Journal of Surgery. https://doi.org/10.1007/s00268-009-0142-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.